| Company Name: | Coley Pharmaceutical Group, Incorporated | | Ticker Symbol: | COLY | | | WWW Address: | www.coleypharma.com |
| CEO: | Robert L. Bratzler, Ph.D. | | No. of Employees: | 150 |
| Common Issue Type: | CS | | Business Description: | A biopharmaceutical company focused on discovering and developing a novel class of drug candidates for several disease indications including cancers, asthma and allergic disorders, and to enhance the effectiveness of vaccines.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | |  | | | | 8.02 | 7.99 | |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 0.0 | 26.6 | -3.15 | -1.13 | 0.00 | 0.0 | 0.0 | 10.60 - 2.81 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 8.01 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 0.0 | mil |
| Latest Shares Outstanding | 26.6 | mil |
| Earnings pS (EPS) | -1.13 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 134,673 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 25.1 | mil |
| Float as % of Shares Outstanding | 94.5 | % |
| Foreign Sales | | mil |
| Domestic Sales | 20 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 38.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 167.70 | % |
| Gross Profit Margin | 94.4 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | -32.3 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -59.4 | % |
| Current Ratio | 2.9 | |
| Leverage Ratio (Assets/Equity) | 2.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.32 | |
| LT Debt/Total Capital | 14.0 | % |
| Working Capital pS | 2.30 | $ |
| Cash pS | 2.63 | $ |
| Book-Value pS | 1.82 | $ |
| Tangible Book-Value pS | 1.82 | $ |
| Cash Flow pS | -1.24 | $ |
| Free Cash Flow pS | -1.03 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 4.40 | |
| Price/Tangible Book Ratio | 4.40 | |
| Price/Cash Flow | -6.5 | |
| Price/Free Cash Flow | -7.8 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 100 | 1,411 | |
| 4 Weeks | 8.02 | 7.92 | 7.93 | 1.0 | 105 | 1,742 | 24,391 |
| 13 Weeks | 8.02 | 2.81 | 3.39 | 136.3 | 261 | 3,376 | 195,798 |
| 26 Weeks | 8.02 | 2.81 | 3.48 | 130.2 | 252 | 2,175 | 265,357 |
| 52 Weeks | 10.60 | 2.81 | 9.71 | -17.5 | 83 | 2,191 | 541,089 |
| YTD | 8.02 | 7.98 | - | 0.1 | 104 | 777 | 3,109 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 8.00 | 7.99 | 6.51 | 4.56 | 5.85 | -3.15 | -3.23 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 73.1 | 0.5 | 27.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.12 | 0.08 | 35.67 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 71.35 |
| Current Ratio | 4.6 |
| Quick Ratio (Acid Test) | 4.5 |
| Liquidity Ratio (Cash) | 4.44 |
| Receivables Turnover | 15.9 |
| Average Collection Period | 23 |
| Working Capital/Equity | 123.5 |
| Working Capital pS | 3.31 |
| Cash-Flow pS | -1.07 |
| Free Cash-Flow pS | -1.38 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.40 |
| Financial Leverage Ratio (Assets/Equity) | 1.7 |
| Debt Ratio | 42.2 |
| Total Debt/Equity (Gearing Ratio) | 0.05 |
| LT Debt/Equity | 0.02 |
| LT Debt/Capital Invested | 38.2 |
| LT Debt/Total Liabilities | 2.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.27 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.29 |
| Tobin's Q Ratio | 1.74 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -4.70 |
| Enterprise Value (EV)/Free Cash Flow | -3.46 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.40 |
| Price/Book Ratio - LTM | 4.40 |
| Price/Cash Flow Ratio | -6.5 |
| Price/Free Cash Flow Ratio - LTM | -7.8 |
| Price/Sales Ratio | 6.85 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.05 |
| Current Liabilities pS | 0.91 |
| Tangible Book Value pS - LTM | 1.82 |
| Book Value pS - LTM | 1.82 |
| Capital Invested pS | 2.71 |
| Cash pS - LTM | 2.63 |
| Cash Flow pS - LTM | -1.24 |
| Free Cash Flow pS - LTM | -1.03 |
| Earnings pS (EPS) | -1.13 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -180.63 |
| Free Cash Flow Margin 5YEAR AVG | -103.30 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.29 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.28 |
| Return on Capital Invested (ROCI) | -41.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -24.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 94.4 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -0.4 |
| Effective Tax Rate - 5YEAR AVRG. | -0.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 8 |
| Revenue per Employee | 134,673 |
| Net Income per Employee | -198,500 |
| Average Collection Period | 8 |
| Receivables Turnover | 15.9 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 19.30 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.23 |
| Fixed Assets Turnover | 1.85 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.38 |
| Revenue per $ Plant | 4.39 |
| Revenue per $ Common Equity | 0.29 |
| Revenue per $ Capital Invested | 0.28 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 60.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 202.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 202.3 |
|
|  
|
| |
 |  |
